Quick Answer
Sana Biotechnology, Inc. reported Cash And Cash Equivalents At Carrying Value of $71.87 million for the year ending 2025.
- Sana Biotechnology, Inc. showed a decrease of -43.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Sana Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $750.69 million | Q2 2021: $675.14 million | Q3 2021: $433.67 million | Q1 2022: $188.52 million | Q2 2022: $194.66 million | Q3 2022: $163.34 million | Q1 2023: $160.46 million | Q2 2023: $173.79 million | Q3 2023: $168.45 million | Q1 2024: $177.05 million | Q2 2024: $134.96 million | Q3 2024: $127.00 million | Q1 2025: $96.13 million | Q2 2025: $71.27 million | Q3 2025: $103.36 million.
- Over the full 6 years of available data (2020 to 2025), Sana Biotechnology, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 42.4%.
- Historical annual values: Fiscal year 2025: $71.87 million | Fiscal year 2024: $127.57 million | Fiscal year 2023: $133.52 million | Fiscal year 2022: $176.77 million | Fiscal year 2021: $253.03 million | Fiscal year 2020: $124.81 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: